Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PADDLE: Nab-paclitaxel + ramucirumab + nivolumab in advanced gastric cancer after first-line chemoimmunotherapy
jRCT2031220448Phase 2Active, not recruiting
- Sponsor
- Ono Pharmaceutical
- Start
- Feb 2023
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of paclitaxel, ramucirumab and nivolumab in gastric adenocarcinoma, Gastric signet ring cell carcinoma (SRCC) and gastric mucinous adenocarcinoma, sponsored by Ono Pharmaceutical. Primary endpoint: 6-month progression-free survival rate. Started Feb 2023; status: active, not recruiting.
02
Drugs
03
Conditions
gastric adenocarcinomaGastric signet ring cell carcinoma (SRCC)gastric mucinous adenocarcinoma
Beyond the preview
Go deeper on jRCT2031220448.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031220448.